cabozantinib,atezolizumab,pembrolizumab,lenvatinib
exelixis,merck,eisai pharmaceutical,roche
['cosmic021']
#asco22 huge effort by at cosmic021 that confirms the few (if any) role of tki in muc. after leap trial, not many options for vefr-driven combos are expected 
Jefe del Servicio de #Oncología Médica y Director de Investigación Clínica de la Fundación MD Anderson Cancer Center Madrid. Opinions are my own